GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medyssey Co Ltd (XKRX:200580) » Definitions » Cash, Cash Equivalents, Marketable Securities

Medyssey Co (XKRX:200580) Cash, Cash Equivalents, Marketable Securities : ₩11,293 Mil (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Medyssey Co Cash, Cash Equivalents, Marketable Securities?

Medyssey Co's quarterly cash, cash equivalents, marketable securities declined from Dec. 2022 (₩11,565.57 Mil) to Dec. 2023 (₩9,138.99 Mil) but then increased from Dec. 2023 (₩9,138.99 Mil) to Dec. 2024 (₩11,292.68 Mil).

Medyssey Co's annual cash, cash equivalents, marketable securities declined from Dec. 2022 (₩11,565.57 Mil) to Dec. 2023 (₩9,138.99 Mil) but then increased from Dec. 2023 (₩9,138.99 Mil) to Dec. 2024 (₩11,292.68 Mil).


Medyssey Co Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Medyssey Co's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medyssey Co Cash, Cash Equivalents, Marketable Securities Chart

Medyssey Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only 7,961.64 11,077.24 11,565.57 9,138.99 11,292.68

Medyssey Co Semi-Annual Data
Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only 7,961.64 11,077.24 11,565.57 9,138.99 11,292.68

Medyssey Co Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Medyssey Co  (XKRX:200580) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Medyssey Co Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Medyssey Co's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Medyssey Co Business Description

Industry
Traded in Other Exchanges
N/A
Address
129, Hanbang expo-ro, Chungcheongbuk-do, Jecheon-si, KOR, 27116
Medyssey Co Ltd designs, develops, manufactures and markets products for the surgical treatment of spine disorders. It offers products including Thoracolumbar Stabilization, Minimally Invasive, and Interbody Fusion.

Medyssey Co Headlines

No Headlines